slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
12,241-12,300 of 319,975
18
The slide highlights the 'me-too' drug development problem in China.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
19
The slide uses a dual-column layout to contrast market drivers (left) with specific regulatory examples (right).Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
20
The slide uses a stacked bar chart to show survey responses and a callout box for qualitative expert feedback.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
21
The slide uses stacked bar charts to show clinical trial phases over time, with CAGR annotations.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
22
The slide uses a three-row structure to map strategic pillars to real-world examples and qualitative expert validation.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
23
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
24
The chart shows a clear shift in clinical trial focus toward oncology, increasing from 30% in 2016 to 48% in 2022.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
25
Uses a 'Past vs Future' transformation framework to illustrate strategic shift.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
26
The chart highlights factors directly related to commercial attractiveness in green.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
27
The chart uses a 7-point Likert scale. The top 4 categories are highlighted in green.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
28
The slide uses a list format with icons to categorize qualitative feedback from interviews.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
29
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
30
The slide uses a structured table to map trends to operational/technical complexity and their specific implications.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
31
The slide uses a chronological framework to explain the shift from paper-based to integrated digital platforms in clinical trials.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
32
The chart combines a horizontal bar chart for penetration rates with a stakeholder usage matrix.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
33
Includes bilingual survey methodology notes.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
34
The slide uses a combination of quantitative survey data and qualitative expert quotes to validate the trend towards smart clinical trial formats.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
35
The slide tracks the progression of Chinese regulatory guidelines (CDE) towards patient-centric and remote clinical trial methodologies.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
36
The slide uses a split-layout to contrast positive drivers against negative barriers.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
37
The slide uses a visual bridge to connect the 'Likely'/'Highly Likely' and 'Unlikely'/'Not Possible' segments of the survey to their respective rationales.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
38
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
39
The slide uses a circular flow diagram to represent a reciprocal relationship between two market actors.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
40
Survey data from IQVIA/L.E.K. Consulting (N=56).Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
41
The slide uses stacked bar charts to show ranking preferences (Top 1, 2, 3) for destinations and simple bar charts for decision factors.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
42
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
43
The chart displays quarterly deal numbers, showing significant volatility but a clear increase in peak deal activity post-2018.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
44
The slide highlights the trend of international pharma companies licensing innovative assets from Chinese biotech firms.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
45
The slide highlights a strategic shift in MNC R&D presence in China, moving towards collaborative incubation models.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
46
The slide uses a stacked bar chart to represent survey data (N=81) and includes two testimonial quotes from R&D leads.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
47
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
48
The slide uses a lightbulb and question mark icon to signify strategic inquiry.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
49
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
50
The slide presents qualitative interview profiles and quantitative survey respondent demographics.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
51
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
52
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
53
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
54
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
55
The slide serves as a corporate profile/introduction.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
56
This is a resource/reference slide listing various publications.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
57
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
58
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
01
Includes author credits and contact information.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
02
The slide uses a structured table format to map market drivers to their specific impacts.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Situation & ContextLoop · Logic Chain1 hit
03
The chart is a waterfall representation of survey responses regarding future IT outsourcing spend.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Situation & ContextLoop · Logic Chain1 hit
04
The chart uses a stacked bar format to illustrate market growth across three segments: ITO, BPO, and Application development.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Logic Chain1 hit
05
The chart shows a bridge from 100 to 92, with a +5 increase and a -13 decrease.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Logic Chain1 hit
06
The slide highlights a shift in spending towards specialized IT services.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Logic Chain1 hit
07
The slide uses a 100% stacked bar chart to show the shift in revenue mix and its impact on operating profit.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Logic Chain1 hit
08
The slide uses a simple list-in-table format to present strategic imperatives.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Logic Chain1 hit
09
Steering Clear of the IT Danger ZonesSteering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next Steps1 hit
01
RAS likely stands for Robotic Assisted Surgery given the image of a surgical robot.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
02
The slide uses a maturity model/spectrum framework to show the evolution of surgical technology.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
03
The slide uses a structured list format to contrast patient and surgeon benefits.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
04
The slide highlights 'Soft tissue surgical robots' as the focus of the report using a dashed orange box.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
05
The chart uses bubble size to represent the number of global surgical procedures and position on the curve to represent penetration level.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
06
The slide uses a bar chart to visualize market growth and a callout box to highlight the projected market value.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
07
The slide uses a timeline to show competitive entry and a list to summarize the strategic implications of patent expiration.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & Proof1 hit
08
The slide uses a map-based visualization to show market entry timing and competitive landscape by country.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & Proof1 hit
09
The table uses checkmarks to indicate market presence, with a distinction between active sales and presence without sales.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & Proof1 hit
10
The slide uses a circular flow diagram to show how two factors reinforce the central opportunity.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & Proof1 hit